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Consumer health risk assessment for feed additives is based on the estimated human exposure to the
additive that may occur in livestock edible tissues compared to its hazard. We present an approach using
alternative methods for consumer health risk assessment. The aim was to use the fewest possible
number of animals to estimate its hazard and human exposure without jeopardizing the safety upon use.
As an example we selected the feed ﬂavoring substance piperine and applied in silico modeling for
residue estimation, results from literature surveys, and Read-Across to assess metabolism in different
species. Results were compared to experimental in vitro metabolism data in rat and chicken, and to
quantitative analysis of residues' levels from the in vivo situation in livestock. In silico residue modeling
showed to be a worst case: the modeled residual levels were considerably higher than the measured
residual levels. The in vitro evaluation of livestock versus rodent metabolism revealed no major differ-
ences in metabolism between the species. We successfully performed a consumer health risk assessment
without performing additional animal experiments. As shown, the use and combination of different
alternative methods supports animal welfare consideration and provides future perspective to reducing
the number of animals.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Feed additives, including feed ﬂavorings, require a thorough
evaluation of consumer safety (Fig. 1). As presented by the Euro-
pean Food Safety Authority (EFSA, 2012a), such an evaluation can
be seen as a four step process from hazard characterization in
laboratory animals or available literature through to determination
of additive residues in the consumable target species. Step 1 is a
hazard characterization usually done in rats, which will also
include the kinetic and metabolic proﬁling of the additive. Step 2 is
the comparison of these rat data with the kinetics and metabolism
of the feed additive in the target livestock species to determine the
identity and amount of the major metabolites. In case the target
animal would form species-speciﬁc metabolites that were not
present in the laboratory rat, gathering additional toxicological
information about this metabolite would be warranted. Step 3
consists of determination of relevant residue levels in the edibleInc. This is an open access article utissues of livestock. In Step 4, the risk characterization for the feed
additive is derived based on the exposure of the consumer to the
substance and its metabolites' via edible tissues that is then
compared to the Health Based Guidance Values such as the
Acceptable Daily Intake (ADI) derived from toxicological studies.
Brieﬂy, step 1 requires gathering the relevant toxicological
(hazard) information either from literature (original literature and/
or reviews from competent bodies such as EFSA or the Joint FAO/
WHO Expert Committee on Food Additives (JECFA)) or from spe-
ciﬁcally designed toxicological studies, step 2 requires metabolism
studies in laboratory rat and target species using radiolabelled
material. Step 3 requires the feeding of livestock animals followed
by collection of their edible tissues for analytical determination of
the residues' concentrations. Following the EFSA guidance docu-
ment (EFSA, 2012a) such an evaluation will require a rather
extensive use of both laboratory animals and livestock animals for
meeting the experimental objectives. Under normal farming con-
ditions, the target species animals would be marketed; however,
because of the nature of the experimental conditions, the remains
of the animals must be discarded.
With the current increased emphasis on reducing the use ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
ADI acceptable daily intake
AI active incubations
AROD alkoxyresuroﬁn-O-dealkylase
BROD benzyloxyresuroﬁn-O-debenzylase
EROD ethoxyresuroﬁn-O-deethylase
ECHA European Chemicals Agency
EFSA European Food Safety Authority
EMA European Medicines Agency
EPA Environmental Protection Agency (USA)
HPV High Production Volume Chemicals Program
HDC heat deactivated control
HPLC high performance liquid chromatography
IPCS International Program on Chemical Safety
JECFA Joint FAO/WHO Expert Committee Report on Food
Additives
LC-MS liquid chromatography-mass spectrometry
L(O)AEL lowest (observed) adverse effect level
LOQ limit of quantiﬁcation
MoE margin of exposure: N(L)OAEL/exposure
MRTD maximum recommended therapeutic dose
NTP National Toxicology Program
N(O)AEL no (observed) adverse effect level
n.a. not applicable
PROD pentoxyresoruﬁn-O-depentylase
PBPK physiologically based pharmacokinetic
(Q)SAR (quantitative) structure activity relationship
RP reverse phase
TTC threshold of toxicological concern
TdB transfer database
UV ultraviolet
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case study of a modiﬁed approach to the safety assessment of feed
additives thereby using and combining alternative methods. While
the overall focus must remain on safety to the consumer, by
providing alternative approaches for each step in the hazard char-
acterization process, the current evaluation demonstrated that it is
possible to reduce or avoid animal studies.
Information for hazard characterization can be obtained from
literature from entries in databases such as that available from the
European Chemicals Agency (ECHA). However, it may be that theFig. 1. Graphical outline of the risk assessment approach used in this feasibility study:
For hazard evaluation (step 1), use all available information such as literature or in
silico computational tools to derive a NOAEL/Health Based Guidance Value. If necessary
consider using the TTC concept or perform dedicated toxicology studies. For evaluation
of comparative metabolism (step 2), three steps can be used: Part A) literature eval-
uation to identify metabolites of piperine in mammals and chicken. Part B) check
whether the known xenobiotic metabolism pathways relevant for piperine in mam-
mals are reported to occur in chicken thereby including substances with comparable
structure (Read-Across). Part C) if necessary perform comparative in vitro study. The
residual concentration in edible tissues (step 3) can be assessed using the TdB or
experimental analytical data. The resulting residue levels are used to calculate con-
sumer exposure. In step 4, perform safety evaluation by comparing the Health Based
Guidance Value for piperine with the calculated maximum intake and conclude on the
risk for consumer.required information is not or not fully available. For such situations
one can consider using the Threshold of Toxicological Concern
(TTC) approach (Kroes et al., 2004; Munro et al., 2008) in case
exposure is sufﬁciently low. It is also possible to use in silico ap-
proaches to determine possible relevant endpoints, ﬁll data gaps
and calculate/predict toxicological endpoints such as the No
Adverse Effect Level (NAEL), which is key for risk assessment.
Recently, Schilter et al. (2014) developed a decision tree approach
on how and when to use in silico toxicological/hazard data in risk
assessment.
The in vitro assessment of metabolism is possible and is used
frequently. Usually, livers from the relevant species are used to
prepare the in vitro functional metabolic components as found in
the S9-fraction, microsomes, or primary hepatocytes; additionally,
liver slices or liver cell lines are also used. Although such ap-
proaches do require animal tissues, when compared to designed
whole animal studies, these in vitro approaches yield information
from fewer animals and avoid exposure of the animals. The use of
comparative in vitro metabolism studies was recently recom-
mended by the EuropeanMedicines Agency (EMA) as an alternative
to in vivo metabolism studies (EMA, 2011). Likewise also other
Regulatory Agencies clearly recommend a reduction in animal use
and replacement by in vitro approaches (EFSA, 2009; ECHA, 2014).
And, as noted above, predictions onmetabolism inmammals can be
done via in silico models (Schroeder et al., 2011). However, in silico
metabolism predictions tools such as Meteor focus on biotrans-
formation in mammalian species.
Further to the assessment process where residue levels in edible
tissue data are needed, a non-animal approach to addressing these
endpoints could be taken by using physiologically based pharma-
cokinetic (PBPK) modeling (Cortright et al., 2009). It is also relevant
to use databases that allow estimating the transfer of foreign sub-
stances from the livestock diet into edible tissues (Leeman et al.,
2007; MacLachlan, 2011), a concept we will demonstrate in our
approach.
In this paper, we will present a case study of using a combina-
tion of in vitro/in silico methods to perform a safety assessment of
the feed ﬂavoring piperine (EC, 2011, Fig. 2). Because it is a widely
used feed ﬂavoring ingredient, we have limited our focus to the
0.5 ppm piperine as added to poultry feed.
2. Materials and methods
In our approach we have addressed each of the risk assessment
Fig. 2. Chemical structure of piperine and identiﬁed analogs antiepilepsirine and piperonic acid.
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2.1.1. Literature search approach, TTC and Cramer class
determination
For hazard evaluation (step 1), it is possible to use existing data
either from original literature or reviews by competent bodies such
as EFSA or JECFA to identify the appropriate NOAEL or ADI. In case
public information is not sufﬁcient for determination of a NOAEL or
ADI, the respective threshold of toxicological concern (TTC) (Kroes
et al., 2004; Munro et al., 2008; EFSA, 2012c) may be considered
using the TTC decision tree. For most substances, the substance has
to be assigned according to its structure into the Cramer Classes I, II,
or III (Cramer et al., 1978). This can be done using online web-tools
such as ToxTree. The TTC rejects high potency substances such as
steroids or anorganic substances whereas speciﬁc thresholds for
potential genotoxic substances and organophosphates/carbamates
are present.
The literature search was performed using the CAS Registry and
RTECS ﬁles, the STN/Toxcenter online database as well as the
websites of the following organizations: International Programme
on Chemical Safety (IPCS), OECD, Environmental Protection Agency
High Production Volume Chemicals Program (EPA HPV), National
Toxicology Program (NTP), and EFSA. The search terms were
piperine and its CAS number (94-62-2). From the retrieved litera-
ture search hits, the relevant information was extracted with focus
on toxicology/pre-clinical safety and metabolism/tissue concen-
trations in both rats and poultry.2.1.2. In silico predictions of toxicological endpoints and
identiﬁcation of structural analogs
For toxicological endpoints where literature information for
piperine was not available, in silico predictions were performed.
Carcinogenicity was predicted using the models available from the
Lazar website (Helma, 2006). Quantitative toxicological endpoint
(i.e. the NAEL) was predicted using the Maximum Recommended
Therapeutic Dose (MRTD) prediction model also available from the
Lazar website (Maunz and Helma, 2008). In addition, the ToxPredict
similarity search function with a threshold of 0.7 was used to
identify structural analogs. The literature was searched for toxico-
logical data of the identiﬁed structural analogs.2.1.3. Comparative metabolism
For evaluation of comparative metabolism (step 2), we followed
three approaches. Part A) consisted of a literature evaluation to
identify metabolites of piperine in mammals. In Part B) we evalu-
ated the literature on existing metabolism studies for piperine in
chickens thereby we included the identiﬁed analogs (see section
2.1.2). Part C) was added and consisted of comparative in vitro
metabolism studies in liver preparations of both species (see sec-
tion 2.2.2), focused on phase I metabolism as conjugation reactions
(phase II metabolism) is highly related to detoxiﬁcation reactions.2.1.4. In silico modeling for calculation of residual concentrations in
edible tissues
The TNO transfer factor database (TdB) is described by Leeman
et al., 2007. Brieﬂy, the database was constructed from a meta-
analysis of public literature on the transfer of chemicals such as
pesticides, dioxins, furans, biphenyls, heavy metals, mycotoxins,
hormones, veterinary drugs, and nitrosamines from feed into
edible animal commodities. Data gathered and recorded in the
database included the species (e.g. poultry, swine, ruminants), a
chemical's concentration in the feed, feeding periods (animal age
and/or duration), residue levels in the animal's edible products, and
a number of other parameters. The key information derivable from
this database is the transfer factors, which are deﬁned as the ratio
of the concentration of the chemical in the edible animal com-
modity (mg/kg wet weight) to the concentration of the chemical in
the animal feed (mg/kg dry weight). Thus, from the concentration
of a chemical added to feed, a prediction is made on the concen-
tration of the chemical that could be expected to be found in edible
commodities. The compounds included in the transfer database
cover a log Po/w range of 9.4 to 9.5 (personal communication) by
which both hydrophilic and lipophilic compounds are about
equally present. Moreover, it was demonstrated that transfer is
related to the log Po/w, showing accumulation of compounds in the
log Po/w range between 3 and 8 only. Therefore the transfer
database can be used for a worst case estimation for transfer of
hydrophilic and lipophilic compounds from feed to edible com-
modities. Speciﬁcally, one transfer factor is assigned to a substance
and edible animal commodity. It should be noted that the transfer
database does not predict metabolism of chemicals, as such the
transfer from feed to food is considered for piperine only.
The transfer factors speciﬁc for piperine are not present in the
database and had to be derived fromvalues available for substances
with a similar log Po/w (±0.5) within the database. The log Po/w of
3.69 was used for piperine for the in silico modeling. This log Po/w
is an estimated value retrieved from ChemIDPlus and conﬁrmed by
EPA EPI Suite software (V4.00). It should be noted that this additive
is intended for use only in feed for broilers so a reﬁnement in the
selection of data was made to cover poultry data only. Piperine is
added to the target species' feed at a concentration of 0.5 ppmwith
a maximum feeding period of 42 days in broiler chicken. Therefore,
a further reﬁnement was made by selecting data covering a limited
feeding period of 1e50 days. Considering the log Po/w of the con-
cerned substances, animal species and relevant exposure periods,
transfer factors were derived from the database for eggs, meat, fat
and the edible organs liver and kidney.2.1.5. Exposure assessment and risk characterization
From the in silicomodeling of worst case residual piperine levels
in edible tissues (section 2.1.4) and from the experimentally
determined residual concentrations (section 2.2.3), we calculated
consumer exposure by using the guidance for exposure assessment
of feed additives brought forward by EFSA (EFSA, 2012a). As the
ﬁnal steps we have performed the risk evaluation and compared
the estimated Health Based Guidance Value for piperine with the
calculated maximum intake.
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2.2.1. Chemicals
Piperine (CAS 94-62-2) was obtained from Acros Organics (pu-
rity: 98.7%). Capsaicin was obtained from Sigma (product number
360,376); testosterone (purity: >99.9%) was from SigmaeAldrich.
For the poultry feeding studies (see section 2.2.3), CRINA® Poultry
Plus, containing 0.1% piperine, was added in amounts up to
4500 ppm in the feed.
2.2.2. In vitro experiments
2.2.2.1. Animals used for preparation of liver fractions. For the
in vitro experiments livers from male Crl:WI (Han) Wistar rats
(Charles River, Sulzfeld, Germany) and female Leghorn Braun
chickens (obtained from a local farmer) were used. The animals
were not pre-treated with enzyme inducers before sacriﬁce.
2.2.2.2. Preparation of liver S9-fraction and liver microsomes for
in vitro metabolism experiments. Liver samples fromhen or ratwere
cut into small pieces, mixed with homogenization buffer (saccha-
rose (250 mM), EDTA-Na2 (1 mM)), and homogenized with a Potter
Elvehjem homogenizer. Raw cell compartments were separated by
centrifugation at 9,000 g (15 min/4 C), which yielded the S9-
fraction in the supernatant. The microsomes were collected via
sedimentation from the S9-faction by centrifugation at 100,000 g
(60 min/0e4 C), washed with washing solution (KCl, 150 mM) and
re-centrifuged at 100,000 g (60 min/0e4 C). Re-suspension buffer
(glutathion 1 mM; EDTA, 1 mM; MgCl2  6H2O, 4 mM; KH2PO4,
0.1 M; glycerol, 20% (v/v), adjusted to pH 7.5) was added to the
pellet, which was then re-homogenized.
The rat or hen liver preparations were characterized using the
following parameters: protein content according to Bradford, to-
tal cytochrome P450 content according to Omura and Sato
(1964a,b), and AROD-activities according to Lubet et al. (1990).
Since liver microsomes are integral constituents of the S9-fraction
and contribute essentially to their metabolic activities, the char-
acterization of a liver S9-fraction is simultaneously addressed by
the characterization of the associated microsomes prepared from
that S9-fraction. This characterization was done to guarantee
valid microsome preparations compared to internal, historical
controls.
The rat liver microsomes were characterized as follows: total
protein content 18.4 mg/mL; cytochrome b5-content 0.5 nmol/mg
protein; total cytochrome P450 content 0.6 nmol/mg protein; and
EROD, PROD, and BROD-activities were 29.1, 22.4, 63.3 pmol/min/
mg protein, respectively. The hen liver microsomes were charac-
terized as follows: total protein content 18.4 mg/mL; cytochrome
b5-content 0.2 nmol/mg protein; total cytochrome P450 content
<0.01 nmol/mg protein; the EROD and PROD-activities were 0.4
and 0.3 pmol/min/mg protein, respectively. BROD activities were
not detectable.
2.2.2.3. Incubation of S9-fraction and microsomes with piperine.
Piperine at a nominal concentration of 100 mM and 10 mM were
each incubated with the liver microsomes and the S9-fractions
obtained from rat or hen. Incubations with microsomes were car-
ried out with 0.5 mg microsomal protein/mL incubate. For in-
cubations with S9-fraction, 250 mL/mL incubatewere used. Piperine
in DMSOwas added at a ﬁnal DMSO concentration of 2.5% (v/v). The
incubations were performed at 37 C for 2 h including 30 mL/mL
incubate of a NADPH-regeneration system. The NADPH-
regeneration system contained glucose-6-phosphate mono-
sodium salt 131 mg/mL, NADPH 33.3 mg/mL, MgCl2 1 M (143 mL/
mL), and glucose-6-phosphate-dehydrogenase 200 mL/mL (¼ 140
units).In addition, appropriate controls were processed under identical
incubation conditions: (i) testosterone as positive control at
200 mM without addition of piperine, (ii) heat-deactivated (100 C,
about 10 min) controls with piperine, and (iii) buffer controls with
piperine but without microsomes or S9-mix. Further, an extraction
efﬁciency control was used that was not incubated but immediately
stopped using acetone. After incubation, the proteins were
precipitated by adding 1 volume of acetone and centrifuged. From
the resulting supernatant, an aliquot was taken for HPLC-UV-
analysis. All incubations were carried out in two replicates.
Testosterone was incubated in parallel and used as a positive con-
trol to show the validity of the test system.
2.2.2.4. Analysis of metabolites in incubates of liver S9-fraction or
microsomes. Piperine and its metabolites were separated by HPLC
(HP 1200) with UV detection (240 nm) using a Gemini 5m C18,
150 3mm column. Gradient elutionwas a mixture of acetonitrile/
0.1% HCOOH: v/v (A) and deionizedwater/0.1% HCOOH: v/v (B) with
a constant ﬂow rate in all steps of 0.6 mL/min. The gradient was as
follows: 0e1 min: kept at 95% B; 1e35 min: gradient change to 10%
B; 35e40min: kept at 10% B; 40e45min: gradient change to 95% B;
45e55 min: kept at 95% B.
The positive control testosterone and its metabolites were
separated by HPLC (Waters Aliance) with Purospher RP18,
150  4 mm column and UV-detection (240 nm). Gradient elution
was a mixture of deionized water/25% methanol/0.1% HCOOH: v/v/
v (A) and deionized water/63.5% methanol/1.5% acetonitrile/0.1%
HCOOH: v/v/v (B) with a constant ﬂow rate of 0.7 mL/min in all
steps. The gradient was as follows: 0e10 min: kept at 25% B;
10e35min: gradient change to 100% B; 35e50 min: kept at 100% B;
50e60 min: gradient change to 25% B; 60e70 min: kept at 25% B.
2.2.3. Residue measurements in in vivo target animal safety studies
Livers were obtained fromRoss 308 broiler chicken of both sexes
that from hatch until 35 days of age were treated with CRINA®
Poultry Plus at dietary concentrations of 0, 450 and 4500 ppm in a
target animal safety/tolerance study. CRINA® Poultry Plus is a
preparation of ﬂavoring substances used for animal feed and con-
tains amongst others piperine (0.1%). Thus, the piperine concen-
trations fed to the animals were 0, 0.45, and 4.5 ppm. The birds
were housed separated by sex and had unrestricted access to a
pelletized broiler diet and drinking water. Each dose group con-
sisted of 8 replicate pens (4 pens per sex) with each replicate pen
containing 20 birds. On day 0, ﬁve birds per pen were randomly
pre-selected. On day 35, the pre-selected birds were sacriﬁced.
Their livers were collected, put on ice and subsequently stored
at 20 C until analysis of piperine content. In total 20 liver per sex
were analyzed in the control and 40 animals in the low dose group
for the presence of piperine. In the high dose group in total 13 birds
were analyzed with a minimum of 1 bird per pen. It was not
considered necessary to analyze the remaining livers because all
samples were below the LOQ.
Before analysis, the liver samples were thawed at room tem-
perature in the dark. An amount of 50 mL of internal standard so-
lution (capsaicin) was added to about 200 mg of liver tissue,
followed by 1.5 mL of ethyl acetate. The mixture was homogenized
using Precellys system and centrifuged. Afterwards 1 mL of the
supernatant was evaporated to dryness and then dissolved with
150 mL of acetonitrile. An amount of 10 mL of the mixture was
injected into the LC-MS/MS system.
LC analysis was performed using HPLC system (Agilent, USA)
with a Sunﬁre C18 (50  4.6 mm, dp ¼ 2.5 mm, Waters) column.
Gradient elution was a mixture of 20 mM ammonium acetate (A)
and acetonitrile (B) with a constant ﬂow rate of 0.8 mL/min in all
steps. The gradient was as follows: 0.00e0.50 min: kept at 20% B;
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25.0e30.0: gradient change to 20% B and 30.0e35.0: kept at 20% B.
A triple quadrupole API 4000 mass spectrometer (AB Sciex, Tor-
onto, Canada) equipped with a Turbo Ionspray (ESI) in positive ion
mode was used. Quantiﬁcation was done by applying external
calibration using internal standard. The criteria for identiﬁcation
and quantiﬁcationwere the retention time andMRM transitionm/z
286/201 for piperine and m/z 306/137 for the internal standard
(capsaicin).
3. Results
3.1. Hazard evaluation (step 1)
Using the ToxTree tool, piperine e a non-mutagenic substance
was determined to be a Cramer Class III compound.
Literature ﬁndings: Piperine was reported to be not mutagenic
in the Ames Test (EFSA, 2011), negative in two in vitromicronucleus
(MNT) assays (Singh et al., 1994; Thiel et al., 2014), negative in
several in vivo MNT studies (EFSA, 2011) and in a recently con-
ducted in vivoMNT (Thiel et al., 2014). Kinetic and metabolism data
were identiﬁed for mammalian species including laboratory rat
(Bajad et al., 2002, 2003a; Suresh and Srinivasan, 2010) and human
(Sethi et al., 2009; Hoelzel and Spiteller, 1984; Kakarala et al., 2010).
However, metabolism data in target species were not available.
Piperine was tested in rats for 8 weeks as dietary mixture at con-
centrations approximately equivalent to doses of 10e20 mg/kg bw/
d (Bhat and Chandrasekhara, 1986). In this study, no adverse effects
on hematological and clinical chemistry parameters were seen. In
other experiments focusing on the male reproductive tract, doses
ranging from 1 to 100 mg/kg bw/d given by gavage to male rats for
30 days (Malini et al., 1999; D'Cruz et al., 2005, 2008). The lowest
dose administered, 1 mg/kg bw/d, produced no adverse effects on
sexual organs and sperm. Doses equivalent to 5 mg/kg bw/d or
higher produced reduced weights of male sexual organs including
testis, cauda epididymides, vas deferens, seminal vesicle and
ventral prostate. Sperm counts, motility and viability were reduced.
Histopathologically, desquamation of spermatocytes, round and
elongated spermatids and their accumulation in the lumen of
seminiferous tubules was seen. In a further experiment with a
study design focusing on liver (Gagini et al., 2010), a dose level of
1.12 mg/kg bw/d was given orally for 23 days to rats. The livers of
the animals were examined histopathologically without signiﬁcant
ﬁndings. Recently, EFSA summarized the results of a 90-day study
with piperine. EFSA concluded that the NOAEL of this study was
5 mg/kg bw/d based on a dose-dependent increase in plasma
cholesterol levels in males at the next higher doses (EFSA, 2015).
Standard experimental carcinogenicity studies are not available
for piperine and therefore in silico predictions were performed
using the in silico models available from the Lazar website (Helma,
2006). Piperine was predicted to be a non-carcinogen by those in
silico models. The conﬁdence for the predictions was above 0.025
for 4 out of the 6 models: The DSSTox Carcinogenicity Potency DBS
MulitCellCall and the DSSTox Carcinogenic Potency DBS Mouse
model showed conﬁdence values below 0.025.
Interestingly, several published studies suggest an onco-
preventative activity rather than a carcinogenic activity e a result
which supports the predictions of the absence of carcinogenicity
(Wbra et al., 1992; Selvendiran et al., 2003, 2004, 2005a, 2005b,
2006; Manoharan et al., 2009; Krishnakumar et al., 2009;
Vellaichamy et al., 2009). In these experimental studies, piperine
was administered subcutaneously or orally together with known
carcinogenic substances using intermittent or continuous piperine
exposures at dose levels up to 100 mg/kg bw/d. In none of the
studies did the co-administration of piperine at the doses usedincrease the incidence in benign or malignant tumors in the
investigated organs. In contrast, piperine co-administration
reduced the incidence of tumors, reduced the tumor volumes,
and the tumor burden in animals in most of the studies. Wiseman
et al. (1987), reported an absence of carcinogenic activity in pre-
weanling mice that received 4 intraperitoneal injections and were
then observed for 18 months. The overall weight of evidence
therefore suggests that piperine does not have a carcinogenic
potential.
Conﬂicting results are available in terms of immunomodulation:
The administration of piperine at dose levels of 0, 1.12, 2.25, or
4.5 mg/kg bw for 5 consecutive days to 6-week old male Swiss mice
resulted in a toxicological proﬁle for immunotoxicity as indicated
by reduced relative weights of spleen, thymus, and mesenteric
lymph node, as well as the lower number of white blood cells in the
high dose group. Several functional tests for humoral and cellular
immunity were also performed and indicated changes in immune
function. The authors concluded that the high dose had a consistent
immunosuppressive effect and that the NOAEL from this study was
1.12 mg/kg bw/d (Dogra et al., 2004). In contrast, in mice a pro-
tective effect of piperine on cadmium-induced toxicity to the im-
mune system at comparable dose levels was reported by Pathak
and Khandelwal (2009).
Further information related to pharmacological effects both
in vitro and in vivo are available in the public domain (as reviewed
e.g. by Perez Gutierrez et al., 2013 or Meghwal and Goswami
(2013)). However, with this information a NOAEL for risk assess-
ment cannot be deduced.
Judicious choice of the in vitro dose concentrations relative to
the in vitro biological component's size, collection of culture me-
dium for quantiﬁcation of parent and metabolite free concentra-
tions at different time points during the assays, and their
association to the assay's endpoint, would be relevant for the use of
in vitro information in (quantitative) risk assessment (Schroeder
et al., 2011; Leist et al. 2012, Blaauboer et al., 2012; Bessems et al.,
2014), however, such details were not available.
In conclusion, the most comprehensive study (90-day study in
rats summarized by EFSA (2015)) results in a NOAEL of 5 mg/kg bw/
d whereas adverse effects on male sexual organs were reported at
the same dose by other authors. A dose of 1 mg/kg bw/d was not
associated with toxicity to male sexual organs (Malini et al., 1999;
D'Cruz et al., 2005, 2008). It is not explicitly mentioned in the
EFSA (2015) report whether male reproductive organs were
examined, however, the reported study is a regulatory toxicological
study and therefore the male reproductive organs were most likely
examined. Nevertheless, the available literature data make the
deduction of an overall NOAEL from experimental data difﬁcult
mainly due to conﬂicting and missing information (especially on
the toxicological endpoint reprotoxicity). For the purpose of this
manuscript, we used 1 mg/kg bw/d as a NOAEL. Applying the EFSAs
standard uncertainty factors of 10  10  2 for inter-and intra-
species variations and for extrapolation from subchronic to chronic
exposure (EFSA, 2012b), a Health Based Guidance Value of 5 mg/kg
bw/d can be calculated.
Considering the uncertainty in terms of the NOAEL described
above and because piperine is not genotoxic, we decided to
consider as well the TTC value for Cramer Class III compounds. The
original Cramer Class III TTC threshold was found to be 90 mg/d or
1.5 mg/kg bw/d (EFSA, 2012; Kroes et al., 2004). Recently, the orig-
inal dataset was re-evaluated with focus on organophosphates
including carbamates, organohalogens and remaining Cramer Class
III compounds. This allowed the deﬁnition of a reﬁned Cramer Class
III threshold being 4 mg/kg bw/d (Leeman et al., 2014).
A further possibility is to predict quantitative toxicological
endpoints by using the MRTD model which is available from the
A. Thiel et al. / Regulatory Toxicology and Pharmacology 73 (2015) 73e8478Lazar website (Maunz and Helma, 2008): The predicted MRTD was
0.014 mmol/d which is considered a human LAEL (Schilter et al.,
2014). The predicted MRTD is equivalent to 60 mg/kg bw/
d thereby considering piperines' molecular weight of 285.34 g/mol
and a 70 kg adult person (EFSA, 2012b). Applying a conservative
uncertainty factor of 3 to convert the LAEL into a human NAEL
(ECHA, 2012), this results in 20 mg/kg bw/d which is at the same
order of magnitude as the derived Health Based Guidance Value
and the TTC thresholds for a Cramer Class III compound as dis-
cussed above.
The similarity search using ToxPredict software and a similarity
search threshold of 0.7 revealed two structural related substances:
antiepilepsirine (CAS 23434-86-8) and piperonic acid (CAS 5285-
18-7). Piperonic acid lacks the piperidine group of piperine (Fig. 2).
For both substances comprehensive toxicological data were not
identiﬁed in peer reviewed scientiﬁc literature. Antiepilepsirine has
anticonvulsant properties and has been used for decades in the
treatment of epilepsy in China with therapeutic doses of 10 mg/kg
bw/d. At doses above 200 mg/kg bw/d clinical side effects con-
sisting of mild vertigo, drowsiness, anorexia and/or nausea can
occur (Pei 1999).
3.2. Comparative metabolism from literature (step 2)
3.2.1. Piperine metabolism in rat (Fig. 1, step 2, part A)
In rat urine, the metabolites piperonylic acid, piperonal,
vanillic acid, and piperonyl alcohol were found; in the bile, piperic
acid was found, suggesting that the amide eCO-N-bond was
cleaved (Bhat and Chandrasekhara, 1987). However, the presence
of piperic acid in bile was not conﬁrmed (Bajad et al., 2002) and
the urinary metabolites previously described could not be
conﬁrmed (Bajad et al., 2003b). Instead, in rat plasma and urine a
major metabolite was characterized by MS and 1H NMR: 5-(2,4-
methylenedioxy phenyl)-2E,4E-pentadienoic acid-N-(3-yl propi-
onic acid)-amide resulting from oxidation of the piperidine ring in
the 4-position followed by loss of an ethylene group (see Fig. 5).
In addition, a minor metabolite was proposed to be E,E-1-[5-(3-
methoxy-4-hydroxyphenyl)-1-oxo-2,4-pentadienyl]piperidine
(Bajad et al., 2003a).
In human urine four metabolites were identiﬁed: 5-(3,4-
dihydroxyphenyl)valeric acid piperidide, its 4-hydroxylated deriv-
ative, and 5-(3,4-dihydroxyphenyl)-2,4-pentaidenoic acid piper-
idide as well as its 4-hydroxylated derivative (Hoelzel and Spiteller,
1984). The apparent differences between the metabolites observed
in rats vs. humans may be explained by the stringent conditions
(pH2 adjusted with 4 N HCl) used during metabolite isolation re-
ported by Bhat and Chandrasekhara (1987). This suggests that the
cleavage of the amide bond may have been produced artiﬁcially.
Overall, metabolites observed in rats and humans are consid-
ered to be derived from identical metabolism pathways. The steps
for mammalian metabolism of piperine are: cleavage of an amide-
group (A), hydroxylation of the piperidine ring in position 4 (D),
opening of the benzodioxole group, and reduction of the double-
bonds (Table 1 and Fig. 5).
Metabolism of the structural related antiepilepsirine, studied in
isolated perfused rat liver, resulted in two metabolites: 3,4-
methylene dioxycinnamyl hydroxypiperidine and 4-hydroxy-3-
methoxycinnamyl piperidine (Dong et al., 1989). Information on
themetabolism of piperonic acid was not found; however, it is most
likely the initial metabolite of piperine once the amide-function is
cleaved (Fig. 5, reaction A).
3.2.2. Piperine metabolism in chicken (part B)
Relevant information on chicken metabolism was not available
in the published literature. From the existing primary literature orfrom literature reviews (Pan and Fouts, 1978a and b) on existing
xenobiotic metabolism pathways in poultry, it remained unclear
whether the identiﬁed steps on mammalian piperine metabolism
exist in chicken (Table 1). Metabolism information in target animal
species for the two structurally related substances was not found.
Therefore no prediction of metabolism of piperine in chicken could
be made and subsequently a comparative in vitrometabolism study
was performed.
3.2.3. Comparative in vitro metabolism study using piperine (part
C)
A comparative in vitrometabolism study using male rat liver S9-
fraction and microsomes and female Brown Leghorn hen liver S9-
fraction and microsomes was conducted. Piperine was metabo-
lized using liver microsomes and liver S9-fraction of rats and hens
under the chosen incubation conditions of the study (Figs. 3 and 4).
In each microsomal and S9-fraction incubate of rats and hens,
10e13 metabolites could be separated by HPLC. All metabolites had
shorter retention times in the RP-chromatogram than the parent
compound (retention time for piperine, isomer 1 about 22.6 min
and isomer 2 about 23.0 min) and are therewith more polar than
piperine. The E/Z-isomerization of piperine is a typical behavior
and is also known from other matrices (Ternes and Krause, 2002).
The most polar metabolites have retention times of about
9e11 min. Characteristic patterns of metabolites that occur in both
in vitro metabolism systems of both species elute at about 16e17,
17e18, and 19e20min (Figs. 3 and 4). Ametabolite with a retention
time of 14.9 min was detected in liver microsomes of hens and in
liver S9-fraction of hens and rats. A minor metabolite with a
retention time of 14.3 minwas detected in S9-fraction of hens only.
However, taken together, it can be concluded from the comparison
of the performed in vitro experiments that the observed metabolic
proﬁles of piperine in liver systems of rats and hens are similar.
3.3. Residue levels (step 3)
3.3.1. Residue estimation using the TNO transfer factor database
Piperine was evaluated for its transfer from feed to edible
commodities using the transfer database. No data for piperine were
present in the database. For the case under consideration, the
transfer factor was derived based on the physical chemical prop-
erties of piperine, more speciﬁcally on the log of the octanol:water
partition coefﬁcient (log Po/w). For the log Po/w, a very good cor-
relation with the respective transfer factors is known (Leeman
et al., 2007).
The transfer factors of piperine from feed to edible commodities
were based on 1) the concentration of piperine in the feed, 2) the
transfer derived using the 95th percentile of substances with a log
Po/w in the same range as piperine (range used of ± 0.5), 3) the
relevant animal species, and 4) the relevant exposure duration.
Although the initial approach was for meat, fat, liver and kidney of
broilers only, transfer factors were also calculated for eggs and are
provided as additional information. The results are presented in
Table 2. Based on these transfer factors the piperine concentrations
were calculated for each of the various edible commodities (see
Table 3).
The transfer factors derived from the TdB are all based on 10 or
more data points and are therefore considered of relevance for
piperine. Because the selected dataset of transfer factors are based
on the 95th percentile of the distribution, the calculated residual
piperine concentrations are considered to represent a reasonable
worst case for subsequent consumer risk assessment.
3.3.2. Residue determination by analytical means
The piperine residue concentrations in the edible tissues, as
Fig. 3. Metabolite patterns (HPLC-UV chromatogram) of piperine; 100 mM in liver microsomes from male Wistar-Han Rats and female Leghorn Braun hens: from top to bottom:
Heat deactivated controls (HDC) from rat and hen, Active incubations (AI) from rat and hen, piperine isomers elute after 22.5 and 23 min.
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highest amount. However, these amounts were only in the upper
ppb range, which was used to guide the sensitivity of an analytical
method.
The analytical method developed for residue level measure-
ments in liver had a limit of quantiﬁcation (LOQ) of 0.1 mg/kg
(0.1 ppb). 73 samples from the control (0 ppm), 450 ppm and
4500 ppm CRINA® Poultry Plus groups, corresponding to 0, 0.45
and 4.5 ppm piperine, respectively, were analyzed for piperine. In
each of the analyzed liver samples, the determined concentrations
were below the LOQ.
3.4. Risk assessment (step 4)
A consumer exposure estimate for piperinewas performed using
the calculated worst case residual piperine levels and the actual
measured piperine residual levels based on the in-life exposure
situation. The ﬁrst exposure estimation was designed in aconservative way and therefore we used only the high consuming
persons acute consumptionﬁgures for adult and toddlers as given in
the respective EFSA guidance (EFSA, 2012a) (Table 2). Acute intake
estimates usually result in higher exposure andwere therefore used
also to assess chronic exposures. The acute intake levels for piperine
were calculated to be 1.3 mg/kg bw/d for adults (78 mg/d) and 1.1 mg/
kg bw/d for toddlers (13.2 mg/d) based on the transfer database
estimation, and 0.002 mg/kg bw/d for adults and 0.001 mg/kg bw/
d for toddlers based on the measured concentrations in the broiler
liver (see Table 4). Comparison with available intake data coming
from use of piperine in food, reveals that intakes of piperine by the
consumer is about 0.3 mg/kg bw/d (20 mg/person/d) (EFSA, 2011)
which is in a comparable range andbelow the deducedHealth Based
Guidance Value of 5 mg/kg bw/d, below the original and reﬁned TTC
threshold level of 1.5 mg/kg bw/d and 4 mg/kg bw/d for Cramer Class
III compounds, respectively (Kroes et al., 2004; Leeman et al., 2014).
The intake is also below the predicted human NAEL of 20 mg/kg bw/
d. The highest calculated acute exposure is 1.3 mg/kg bw/d, which
Fig. 4. Metabolite patterns (HPLC-UV chromatogram) of piperine; 100 mM in liver S9 fraction from male Wistar-Han Rats and female Leghorn Braun hens: from top to bottom: Heat
deactivated controls (HDC) from rat and hen, Active incubations (AI) from rat and hen, piperine isomers elute after 22.5 and 23 min.
A. Thiel et al. / Regulatory Toxicology and Pharmacology 73 (2015) 73e8480can be considered as a worst case exposure estimate, and the
resulting margin of exposure (MoE) is 15.4(= 20 mg/kg bw/d / 1.3 mg/
kg bw/d) for the predicted human NAEL. The MoE is high enough to
account for an uncertainty factor of 10 for intraspecies variability
(EFSA, 2012b). The use of further uncertainty factors such as
extrapolation of duration or for interspecies extrapolation is not
considered relevant because we consider comparable exposure
durations. Based on these considerations, the use of piperine as a
feed ﬂavoring at a concentration of 0.5 ppm in chicken feed is
considered to pose no unacceptable risk for consumer.4. Discussion
In this paper we describe combination of non-animal alternative
methods for hazard characterization to fulﬁll the feed additives
guidance for consumer safety assessment as detailed by the EFSA
(2012a). Instead of performing in vivo toxicological, kinetics,
metabolism, and residue studies, we used alternative, non-animal
approaches. These included information from public literature, in
silico predictions of qualitative and quantitative toxicological end-
points, Read-Across techniques to assess metabolism and toxico-
logical endpoints, an in vitro comparative metabolism study and an
in silico-based estimation of residue levels predicted for the edible
tissues.As a case study we selected the feed additive piperine, which
was added in a feeding study to poultry feed at a concentration of
0.5 ppm and a treatment duration of 42 days, themaximum feeding
period for fattening chickens in the broiler stage.
Determination of a Health Based Guidance Value to use for
hazard characterization (Step 1) was attempted by doing a review
of existing data in the published literature which clearly shows the
absence of mutagenicity or genotoxicity. The available literature
consisted of a summary of a regulatory toxicological study, of re-
ports of dedicated studies that investigated speciﬁc endpoints such
as testicular toxicity, chemo-preventive activity or interaction with
the immune system. However, the data were conﬂicting because
the NOAEL from the regulatory 90-day toxicity study (5 mg/kg bw/
d) was reported in the literature to produce adverse effects on male
reproductive organs (EFSA, 2015; Malini et al., 1999; D'Cruz et al.,
2005, 2008). We therefore used as the NOAEL, the dose which
produced no effects on male sexual organs which was 1 mg/kg bw/
d to deduce a Health Based Guidance Value of 5 mg/kg bw/
d considering the guidance from EFSA (2012b). To account for the
above mentioned uncertainties, we used the TTC concept as
described by Kroes et al. (2004) in addition. Piperine is a Cramer
Class III substance for which a threshold of 1.5 mg/kg bw/d is
considered to be the systemic exposure threshold below which
toxicity concerns are minimal. In addition, we estimated a Health
Fig. 5. Metabolites of piperine described for mammals.
Table 1
Comparison of principal metabolic pathways of piperine.
Major metabolism step in mammals Occurrence in chicken for the following substances
A: Cleavage of amide-group No data
B: Opening of the1,3-benzodioxole group No data
C: Reduction of double-bonds No data
D: Hydroxylation of piperidine ring in position 4 with/without loss of ethylene group No data
Table 2
Calculated transfer factors for chicken products using the TNO transfer factor
database.
Animal product GM GSD Median P90 P95 P99 N Max
Eggs 0.03 0.04 0.01 0.11 0.14 0.16 29 0.16
Meat 0.02 0.04 0.00 0.03 0.19 0.19 17 0.19
Fat 0.01 0.01 0.01 0.03 0.04 0.04 14 0.04
Edible offals 0.09 0.20 0.02 0.18 0.29 0.99 25 0.99
GM: geometric mean.
GSD: geometric standard deviation.
Pxx: xxth percentile.
N: amount of data underlying the statistical data.
Max: maximum transfer factor found for the selected dataset.
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dicted theMRTD that was converted into a human NAEL of 20 mg/kg
bw/d.
For step 2, which is the comparison of metabolites formed in
rats versus those seen in poultry, based only on available literature
we could not reach what we considered to be a reliable conclusion.
From the review of Pan and Fouts (1978a and b) it is evident that
many of themetabolism steps occurring in rats, such as conjugation
of phenolic compounds with sulfate or glucuronic acid, conjugation
of carboxylic acids, or ester hydrolysis, are also well documented in
poultry. However, from the literature we could not conﬁrm that
poultry would use the major steps for piperine metabolism found
in mammals, including amide-bond cleavage, hydroxylation of a
piperidine-ring or opening of a benzodioxole group (see Table 1 and
Fig. 4). Likewise, no metabolism data of structural analogs in
Table 3
Calculated versus measured residue levels of piperine in liver.
Concentration in feed Calculated concentration in edible commodity using TNO transfer model Measured concentration in liver
Egg Meat Fat Kidney and liver
(ppm) (mg/kg wet weight)
0.5 0.07 0.1 0.02 0.15 <0.0001
The concentrations in edible commodity (mg/kg wet weight) were calculated as follows: transfer factor (see Table 2) x concentration of the substance in the animal feed (mg/
kg dry weight (ppm)).
Table 4
Acute adult and toddlers exposure estimates based on calculated residue levels and comparison with TTC level.
Population Reference level for risk
assessment
Consumer exposurec resulting from consumption of edible chicken tissues based on
TTC ADI Calculated worst case residue levelsa Measured residue levelsb
(mg/kg bw/d)
Adults 1.5 n.a. 1.3 0.002
Toddlers 1.5 n.a. 1.1 0.001
a Using calculated residue levels speciﬁed in Table 3.
b Using measured residue levels speciﬁed in Table 3 thereby assuming identical amounts in each tissue. From the TdB data it can be argued that other edible commodities
contain less residue than liver.
c Consumer exposure was calculated for high consuming adult and toddlers thereby assuming acute exposure to reﬂect worst case. According to EFSA guidance (EFSA,
2012a) the following consumption data are applicable for this exposure scenario: toddlers weighing 12 kg consume 135 g meat/day; adults weighing 60 kg consume
390 g meat/day, 170 g liver/day, 100 g kidney/day, 40 g fat/day, eggs not given.
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an in vitro metabolism comparative study that clearly showed
similar metabolites proﬁles for rat and chicken (Fig. 3). The results
of this in vitro metabolism study together with the available liter-
ature information increased the level of conﬁdence that the rat
metabolism study was a reliable predictor of poultry metabolism of
piperine.
Overall, from our experience with the present study, the scope
of our approach would be more widely applicable if the metabolic
pathways for a broader number of species were readily available
and accessible. Expansion of existing databases beyond poultry to
other consumable livestock such as ﬁsh or ruminants would pro-
vide a useful platform for further development of a reduced animal
approach to food or feed additives risk assessments.
For step 3, we successfully used the TdB to estimate the worst
case piperine residual amounts in edible tissues. The use of the TdB
allowed us during determination of residues under normal in-life
situations to focus on the tissue with the expected highest resid-
ual concentration. Another helpful informationwhichwas obtained
from the TdBwas the required sensitivity of themethod for analysis
because clear guidance is given on the required sensitivity of the
analytical method. The use of the 95th percentile of the database
distribution on residual piperine levels in edible tissues conﬁrmed
the assumed conservative (worst case) residue estimations by the
TdB, being considerably higher than the actual measured concen-
tration in tissues from exposed target animals under normal in-life
conditions. Thus, using the transfer database from a food safety
perspective was also shown to be suitable.
In step 4, we demonstrated, using the guidance from EFSA
(2012a), that the consumer's calculated intakes of piperine were
considerably lower than the estimated Health Based Guidance
Value, the TTC value and the predicted NAEL. Therefore, we
concluded that piperine could be safely used in poultry nutrition at
the routinely applied dietary concentrations.5. Conclusion
In this case study with the feed additive piperine, we havesuccessfully used a combination of in vitro/in silico based alternative
methods for the consumer risk assessment. Our approach is based
on (i) read-across techniques to assess metabolism in target animal
complemented with in vitro comparative metabolism work, (ii)
calculated residual concentrations derived from a database thereby
using worst case i.e. highest distributions within the database, and
(iii) comparison of the determined exposure with the derived
Health Based Guidance Value, the respective threshold of the TTC
concept and/or predicted quantitative toxicological endpoints. The
in silico residue modeling used for piperine showed to be a worst
case approach: the modeled residual levels were considerably
higher as compared to the measured residual levels. This strategy
provides an alternative to animal testing without jeopardizing
consumer safety. The use of in vitro/in silicomethods may therefore
also serve in future for risk assessment for other feed additives and
was shown that the alternative methods results in conservative
outcomes.
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